baber/WOPTO huggingface dataset:
Patent NZ-278931-A (NZ)
Title: Electronic toll payment; system which identifies an electronic purse and effects value transfer over a communication system
Inventor: EVERETT DAVID BARRINGTON
IPC: H04Q7/32
Filed: 1995-02-01
Abstract: PCT No. PCT/GB95/00198 Sec. 371 Date Oct. 3, 1996 Sec. 102(e) Date Oct. 3, 1996 PCT Filed Feb. 1, 1995 PCT Pub. No. WO95/21424 PCT Pub. Date Aug. 10, 1995A system for toll payment by electronic cash identifies an electronic purse and effects value transfer over a communication system without stopping the mobile (vehicle or person). Mobile identity MID is temporarily correlated with purse identity PID and one or another identity is erased on satisfactory or non-satisfactory completion of the transaction thereby allowing non-payers to be pursued while preserving the principle of anonymity.
Patent NZ-279734-A (NZ)
Title: Racemization of piperazine-2-t.butylcarboxamide derivatives
Inventor: ROSSEN KAI
IPC: A61K31/495
Filed: 1995-01-30
Abstract: A process for racemization of optically pure or enriched piperazine-2-tert-butylcarboxamide and its derivatives comprising reacting the optically pure or enriched piperazine compound with a racemizing agent selected from a strong base, an anhydrous metal salt or a carboxylic acid, in a solvent at a temperature range of between room temperature and 250 DEG  C. The piperazine carboxamide derivatives are key intermediates in the preparation of HIV protease inhibitor compounds, including Compound J.
Patent NZ-334389-A (NZ)
Title: Cyclic amine derivatives
Inventor: ASAI FUMITOSHI
IPC: C07D207/12
Filed: 1997-07-28
Abstract: Provided are compounds of the formula R1-C(R2)-R3 wherein: R1 is an optionally substituted phenyl; R2 is an optionally substituted aliphatic acyl or benzoyl group, or an alkoxycarbonyl group; and R3 is a substituted 3 to 7 membered saturated cyclic amino group, which may be in the form of a fused ring; and salts thereof. These compound are reported to possess platelet aggregation inhibitory action and arteriosclerosis progress inhibitory action.
Patent NZ-336116-A (NZ)
Title: Diagnostic agent comprising an amino acid or peptide containing at least one 13C or 14C for pancreatic exocrine function
Inventor: KOHNO TADASHI
IPC: C07K5/065
Filed: 1999-06-03
Abstract: A diagnostic agent for testing pancreatic exocrine function.  The agent comprises an amino acid or a peptide containing at least one 13C or 14C atom with the proviso that the pharmaceutical salt is not Bz-Tyr-13C-PABA.  The amino acid is represented by the following formula (I):  X1-R1-Y1  Wherein X1 is a hydrogen atom or a protecting group, R1 is a peptide of 2 to 50 amino acids an amino acid or a single bond, Y1 is an amino acid optionally having a protecting group.  The diagnostic agent, upon reaction with pancreatic exocrine protease is decarboxylated to generate 13CO2 or 14CO2 and may be used in a breath test.
Patent NZ-337240-A (NZ)
Title: Preparation of sterol/stanol esters by reacting sterol/stanol with a catalyst, acid and color deactivating agent
Inventor: RODEN ALLAN
IPC: A61K31/575
Filed: 1999-08-13
Abstract: A method for producing stanol/sterol esters comprising reacting a stanol/sterol of the formula 1  and an acid in the presence of a catalyst and a color deactivating agent to form the formula 2 where R1 is a carbon chain having a length C5-25 and R2 is a carbon chain C3-15
Patent NZ-501576-A (NZ)
Title: Mounting frame, typically stretch film roll mounting frame, with inner frame containing roll spindle trunnion mounted to surrounding outer frame
Inventor: TURFAN FARUK M
IPC: B65B11/02
Filed: 1999-12-03
Abstract: A framework 110 of a film wrapping packaging machine has external framework 140 and an internal framework 138 pivotally mounted of the external framework.  Spindle 134 is mounted on the internal framework for supporting a roll of film wrapping material (not shown).
Patent NZ-502211-A (NZ)
Title: Ink-jet recorder and ink cartridge with external control means on exposed surface of circuit board
Inventor: MATSUZAKI MAKATO
IPC: B41J2/175
Filed: 1999-05-18
Abstract: An ink supply needle (6) is provided on one side of the path where a carriage (4) reciprocates. A circuit board (31) is attached to the wall near the side where an ink supply orifice (44) of an ink cartridge (40) is provided. Contacts for connection to external control means are formed on the exposed surface of the circuit board (31). Therefore, even if a clearance is present between the carriage (4) and the cartridge (40), the movement path is restricted by the ink supply needle (6) and the ink supply orifice (44), and the contacts are connected to external control means in a prescribed order. As a result, the data in semiconductor storage means is prevented from being deleted because of application of signals in a wrong careless order.
Patent NZ-502361-A (NZ)
Title: 4-oxo-3,5-dihydro-4H-pyridazino[4,5-b]-indole-1-acetamide derivatives, their preparation and their application in therapy
Inventor: EVANNO YANNICK
IPC: A61K31/50
Filed: 1998-07-28
Abstract: Described are compounds of general formula (I) in which: X represents a hydrogen or halogen atom or a methyl, methoxy or phenylmethoxy group; Y represents a hydrogen atom, one or two halogen atoms or a methyl, hydroxy, methoxy or nitro group; R1 represents a hydrogen atom or a (C1-C4) alkyl group; R2 and R3 each represent, independently of one another, a hydrogen atom, a (C1-C4) alkyl group or a phenyl-methyl group; or R2 and R3 form, together with the nitrogen atom bearing them, an azetidinyl, pyrrolidinyl, 3-ethoxy-pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or 1,3-thiazolidinyl group. They can be used for treating diseases related to GABAergic transmission disorders, such as anxiety, sleep disorders, epilepsy, spasticity, muscle contractures, cognitive disorders related to alcoholism, tobacco or drugs, and the like.
Patent NZ-507193-A (NZ)
Title: Improved low residue cosmetic antiperspirant deodorant composition
Inventor: POTECHIN KATHY J
IPC: A61K8/00
Filed: 1999-03-31
Abstract: Describes a method comprising low residue cosmetic compositions (especially underarm products) which are made by combining an active ingredient; a silicone gel material itself comprising an elastomer composition; and at least one selected surfactant having an HLB value in the range of 8-16. The compositions of this method exhibit reduced or eliminated film formation when applied to the skin and increased availability of the active ingredient.
Patent NZ-507876-A (NZ)
Title: Blowing head for optical fiber installation in duct with sensor and controller to apply braking to drive motor
Inventor: BARKER PHILIP ALFRED
IPC: G02B6/44
Filed: 1997-09-17
Abstract: A rotation sensor (not shown) determines direction of movement of the rotatable drive wheels 2,3. Controller 19 causes drive motor(s) of drive wheels 2,3 (not shown)  to apply a holding torque to wheels 2,3 to counter rotation opposite to normal rotation.
Patent NZ-515887-A (NZ)
Title: Automatic map-generation and labeling including real-time map generation from details in database
Inventor: REID LAWRENCE JASON
IPC: G06F17/30
Filed: 2001-12-03
Abstract: A computer - Implemented method of automatically positioning labels for features of an electronically rendered map comprises the steps of: storing a structural representation of the map features from in computer memory, one or more of the map features associated with a label, rendering one or more of the map features from the structural representation in a graphic representation, for one or more of the map features rendered, determining a placements for the associated label in the graphic representation, defining the set of label placement to be the current labeling solution, evaluating whether the current labeling solution is optimal by applying an objective function, and while the result of the objective function is sub-optimal performing the steps of: producing a plurality of alternative labeling solutions from the current solution by performing at least one transformation on one or more of the label placements, evaluating each alternative labeling solution with the objective function , selecting the best solution as the new current solution, and evaluating whether the current map labeling solution is optimal by applying the objective function.
Patent NZ-519397-A (NZ)
Title: Digging tool
Inventor: CAMERON MICHAEL JOHN
IPC: A01B1/00
Filed: 2002-06-06
Abstract: A tool (1) comprising a handle (2), a blade (12) having a cutting edge (13) and receiving means (14), and an actuation assembly (5) having a first portion capable of attaching to the handle and a second portion capable of attaching to the receiving means of the blade thereby providing a pivot portion about which the handle and blade can move. The blade is removable with respect to the second portion. Addition to 509849
Patent NZ-520029-A (NZ)
Title: Viscous drag impeller components incorporated into pumps, turbines and transmissions
Inventor: DIAL DANIEL CHRISTOPHER
IPC: F04D17/16
Filed: 2000-12-20
Abstract: The present invention is for the efficient transfer of mechanical power through a fluid medium. The various embodiments of the present invention exploit the natural physical properties of fluids to create a more efficient means of driving fluids as well as transferring power from propelled fluids. The present invention employs an impeller assembly in a variety of applications including hydroelectric turbines, fluid turbines, turbine transmissions and pumps of various types. The multi-disk impeller assembly having a central cavity, a specialized central hub design and reinforcing backing plates contribute to greater efficiency and less turbulence, friction and noise
Patent NZ-528338-A (NZ)
Title: Biosensors for detecting bond rupture
Inventor: YUAN YONG
IPC: G01N21/55
Filed: 2004-03-19
Abstract: A biosensor with a separate oscillator and rupture detector. The biosensor includes a surface onto which bio-macromolecules are bound, the surface and bio-macromolecules being immersed in liquid, a bond rupture detector associated with the surface, and an oscillator associated with the liquid and spaced from the surface and arranged to produce waves in the liquid to cause bonds between the bio-macromolecules and the target substance to rupture. A surface plasmon resonance detector detects rupture of the bonds by changing the angle of reflected light that has minimum reflectance.
Patent NZ-532577-A (NZ)
Title: Methods for detection of target molecules and molecular interactions between nucleic acid tags attached to binding entities specific for the target molecules of interest
Inventor: WILSON STUART
IPC: C12Q1/68
Filed: 2002-10-03
Abstract: Methods of detecting target molecules are described together with the interactions between target molecules based on interactions between proximally-bound nucleic acid tags. Reagent kits for use in such methods are also provided. Figure 3 illustrates an exchange of sequence between the nucleic acid tags that results in a previously unknown detectable sequence. Examples of such detectable sequences include nucleic acid amplification primer binding sites or RNA polymerase binding sites, i.e., promoters that allow detection of the sequence by amplification. The sequences that promote the exchange of sequence are shown as triangles. One system that could be used is the phage lambda-based site-specific recombination system. In this example, the attL and attR recombination sequences recombine in the presence of recombinase to generate attP and attB.
Patent NZ-533958-A (NZ)
Title: Deazapurines and uses thereof
Inventor: DAUN JANE
IPC: A61K31/55
Filed: 2003-01-07
Abstract: Disclosed is a compound having the structure (I) and pharmaceutically acceptable salts thereof, wherein: n is an integer from 0-4; R1 is hydrogen, -NH2, -NHMe, -NHAc, -OH, F, -OMe, -CN, or - NH(C=O)OEt; R2 is hydrogen, -NRARB, -ORA, C1-20alkyl, C1-20alkenyl, C1-20haloalkyl, C3-14aryl, or C3-14heteroaryl, wherein C3-14aryl or C3-14heteroaryl may be independently unsubstituted or substituted with one or more substituents selected from the group consisting of C1-20alkyl, C1-20alkoxy, and C1-20thioalkyl; each occurrence of R3 is independently hydrogen, halogen, CN, C1-20alkyl, C1-20alkoxy, C1-20thioalkyl, C3-10cycloalkyl, C3-14aryl, C3-14heteroaryl or -G-RC; G is absent or is -CH2-, -(CH2)2-, -CH=CH-CH2-, -CH=CH-, -C=C-, -O- or (C=O); RC is hydrogen, -NRFRG, -(CH)RFRG, -ORF, -SRF, -S(=O)RF, -S(=O)2RF, C1-20alkyl, C1-20alkenyl, C1-20alkynyl, C3-10cycloalkyl, C3-10cycloalkenyl, C3-10cycloalkynyl, heterocycle, aliphatic moiety, C3-14aryl or C3-14heteroaryl; and the remaining substituents are as defined in the specification. Also disclosed are pharmaceutical compositions containing the compounds which are suitable for the inhibition of the inflammatory cytokine pathway, cell proliferation or inflammation.
Patent NZ-536182-A (NZ)
Title: Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors
Inventor: VENKATESAN ARANAPAKAM MUDUMBAI
IPC: A61P31/04
Filed: 2003-04-30
Abstract: Disclosed herein are bicyclic 6-alkylidene penems of formula (I) which act as a broad spectrum beta-lactamase inhibitors, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof, wherein the variables shown in formula (I) are as defined in the specification.
Patent NZ-539713-A (NZ)
Title: Implantation of encapsulated biological materials for treating diseases
Inventor: SCHARP DAVID
IPC: A61K35/12
Filed: 2003-10-14
Abstract: Disclosed is a composition comprising a plurality of encapsulating devices comprising a polymerizable high density ethylenically unsaturated polyethylene glycol (PEG) having a molecular weight between 900 and 3000 Daltons and a sulfonated co monomer; and a plurality of cells encapsulated in the encapsulating devices, wherein said composition has a cell density of about 100,000 cells/ml.
Patent NZ-540722-A (NZ)
Title: Process for the preparation of pyrimidine compounds and intermediates thereof
Inventor: NEWTON LEE
IPC: C07D239/42
Filed: 2003-12-09
Abstract: A process for the preparation of a pyrimidine compound of formula (1) and intermediates useful therein are disclosed. The process comprises reacting a compound of formula R1-CO-CH2-E with a compound of formula R2-CHX1X2 in the presence of a compound of formula R3R4N-C(=NH)NH2 and a catalyst, thereby to form a dihydropyrimidine; and oxidising the dihydropyrimidine to form the compound of Formula (1). R1 is H or an alkyl group; R2 is H, an alkyl or aryl group; R3 and R4 are each independently H, alkyl or aryl, or R3 and R4 are linked to form, together with the nitrogen to which they are attached to form a 5 to 7 membered heterocyclic ring; E is H, an unsubstituted alkyl group, an aryl group or an electron withdrawing group; and X1 and X2 are each independently leaving groups, or X1 and X2 together represent =O.
Patent NZ-544751-A (NZ)
Title: Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
Inventor: WILD KENNETH D
IPC: G01N33/53
Filed: 2004-07-15
Abstract: Disclosed are isolated human antibodies that bind specifically to nerve growth factor (NGF). These antibodies can be used to neutralize NGF function and particularly to treat NGF-related disorders (e.g. chronic pain). Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Patent NZ-546108-A (NZ)
Title: A spacer and method of venting a circuit breaker
Inventor: BAIN JOHN WILLIAM
Filed: 2006-02-16
Abstract: A spacer 10 for providing venting for a circuit breaker engaged with a fuse base is disclosed. The spacer is located within the fuse base while still allowing the circuit breaker, which has a vent hole, to engage the fuse base. As a result the circuit breaker is spaced from the fuse base a sufficient distance to allow unobstructed venting through the vent hole.
Patent NZ-547172-A (NZ)
Title: Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same
Inventor: KLEEMANN HEINZ-WERNER
IPC: C07C381/00
Filed: 2004-11-03
Abstract: The disclosure relates to pentafluorosulfanyl benzoylguanidines of formula (I), in which R1 to R4 correspond to meanings given in the specification. These pentafluorosulfanyl benzoylguanidines are suitable for use as anti-arrhythmic medicaments comprising cardio-protective components for the prophylaxis and treatment of infarcts, in addition to the treatment of angina pectoris. These compounds also preventatively inhibit the pathophysiological events that occur during ischaemically induced traumas, in particular during the triggering of ischaemically induced cardiac arrhythmia.
Patent NZ-550204-A (NZ)
Title: Barley plant with mutant LOX-1 protein, for production of flavor-stable beverage
Inventor: BREDDAM KLAUS
IPC: A23L35/00
Filed: 2005-03-09
Abstract: Disclosed are barley plants which exhibit null LOX-1 activity. The said plants are characterised in that they comprise a mutated LOX-1 enzyme lacking all or a portion of amino acids between numbers 520 to 862 or 378 and 665 of wild-type barley LOX-1. In wild-type plants the LOX-1 enzyme accounts for the principal activity related to conversion of linoleic acid into 9-hydroperoxy octadecadienoic acid, a lipoxygenase pathway metabolite, which, through further enzymatic or spontaneous reactions, may lead to the appearance of trans-2-nonenal. The disclosure enables the production of beer that is devoid of detectable trans-2-nonenal-specific off flavours, even after prolonged storage of the beverage. Further disclosed are malt and wort compositions made from said barley plants.
Patent NZ-550304-A (NZ)
Title: An antimicrobial preservative-free albuterol inhalation solution for the relief of bronchospasm in children with asthma
Inventor: CHAUDRY IMTIAZ
IPC: A61K31/137
Filed: 2002-10-18
Abstract: Disclosed is an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of disclosed is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution comprises about 0.63 mg or about 1.25 mg albuterol.
Patent NZ-560432-A (NZ)
Title: Conjugation of streptococcal capusular saccharides
Inventor: BERTI FRANCESCO
IPC: A61K39/09
Filed: 2006-02-01
Abstract: A conjugate comprising a Streptococcus agalactiae capsular saccharide and a carrier molecule prepared by: (a) oxidising a Streptococcus agalactiae capsular saccharide to introduce an aldehyde group into at least one galactose residue in the capsular saccharide to provide one or more modified galactose residue; and (b) Coupling at least one modified galactose residue to a carrier molecule. The conjugate is used for treating disease caused by S. agalactiae.
Patent NZ-562405-A (NZ)
Title: A method for computer based teaching and testing
Inventor: HINGSTON DAVID LEWIS
Filed: 2005-01-28
Abstract: A computer-implemented method of providing a mathematics questions definition includes the steps of a. defining a range of operands to be used in a set of basic facts questions; b. defining at least one operator to be used in the set of basic facts questions; c. defining the size of the set of basic facts questions; d. defining the time allowed for answering the set of basic facts questions; and e. defining a mode. The definition is supplied to a computer program and the computer program generates the set of basic facts questions according to the definition. The mode can be a teaching mode or a testing mode.
Patent NZ-562999-A (NZ)
Title: Method for alignment of analog and digital audio in a hybrid radio waveform
Inventor: IANNUZZELLI RUSSELL
IPC: H04H20/30
Filed: 2006-03-01
Abstract: Disclosed is a method of detecting time alignment of an analog audio signal and a digital audio signal in a hybrid radio system. The method comprises the steps of: filtering the analog audio signal to produce a filtered analog audio signal; filtering the digital audio signal to produce a filtered digital audio signal; and using the filtered analog audio signal and the filtered digital audio signal to calculate a plurality of correlation coefficients. The correlation coefficients are representative of time alignment between the analog audio signal and the digital audio signal.
Patent NZ-565177-A (NZ)
Title: 3-substituted-2-(arylalkyl)-1-azabicycloalkanes and methods of use thereof
Inventor: MAZUROV ANATOLY A
IPC: C07D453/04
Filed: 2004-02-20
Abstract: The present disclosure relates to pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). More specifically the disclosure relates to a racemic mixture of the (R,R; R,S; S,R; and S,S) enantiomers of N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide. The present disclosure also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems wherein the central nervous system disorder is selected from the group consisting of pre-senile dementia (early-onset Alzheimer's disease), senile dementia (dementia of the Alzheimer's type), micro-infarct dementia, AIDS-related dementia, Creutzfeld-Jakob disease, Pick's disease, Parkinsonism including Parkinson's disease, Lewy body dementia, progressive supranuclear palsy, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive compulsive disorders, Tourette's syndrome, HlV-dementia, multiple cerebral infarcts, mild cognitive impairment (MCI), age-associated memory impairment (AAMI), premature amnesic and cognitive disorders which are age-related or a consequence of alcoholism, or immunodeficiency syndrome, or are associated with vascular disorders, attention deficiencies or learning deficiencies, acute or chronic neurodegenerative conditions such as amyotrophic lateral sclerosis, multiple sclerosis, peripheral neurotrophies, and cerebral or spinal traumas, treat nicotine addiction and/or other behavioural disorders related to substances that lead to dependency including alcohol, cocaine, heroin and opiates, psychostimulants, benzodiazepines and barbiturates.
Patent NZ-568720-A (NZ)
Title: Substituted phenethylamines with serotoninergic and/or norepinephrinergic acitivity
Inventor: GANT THOMAS G
IPC: A61K31/135
Filed: 2006-11-30
Abstract: Disclosed is a deuterated 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol (velafaxine) of Formula I or a single enantiomer, a mixture of the (+)-enantiomer and the (-)enantiomer, an individual diastereomer, a mixture of diastereomers, or a pharmaceutically acceptable salt or solvate thereof, wherein: RI, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 , R12, R13, R14, RIS, R16, R17, and RI8 are independently selected from the group consisting of hydrogen, and deuterium; R19, R20, and R21 are independently selected from the group consisting of CH3, and -CD3. Also disclosed is the use of said compound in the treatment of psychotropic disorder, an anxiety disorder, a generalized anxiety disorder, depression, a post-traumatic stress disorder, an obsessive compulsive disorder, a panic disorder, a hot flash, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, a psychiatric disorder, a premenstrual dysphoric disorder, a social phobia, a social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and premature ejaculation.